SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile triggered a sharp selloff in T-Mobile and other wireless carriers as investors weighed the prospect of a new competitor. Traders are divided between seeing a meaningful long-term threat to carrier growth and viewing the decline as an overreaction, since building a competitive network would require substantial infrastructure and time.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation around Patrick Soon-Shiongs upcoming oncology symposium fireside chat is driving attention, with traders hoping for concrete trial updates and other company news. Some also link ImmunityBios cancer-vaccine research to a broader NIH initiative, though claims of an imminent government partnership or deal remain speculation; bullish short-squeeze chatter is prominent as well.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMYs price action and possible breakout are drawing attention, with traders split between dip-buying and warnings that rallies may fade. Bulls point to new JasmyChain activity and ecosystem partnerships as signs of potential utility, while skeptics argue meaningful adoption remains unproven and cite weak performance and exchange delistings.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T shares sold off amid concerns that SpaceXs spectrum acquisition could support a Starlink Mobile service competing with established wireless carriers. Traders debated whether the move signals a meaningful long-term threat or an overreaction, noting the time and infrastructure needed to build a rival network while some viewed the drop as a buying opportunity tied to AT&Ts established business and dividend.

Chevron Corporation. The Group's principal activities are providing administrative, financial and management support for fully integrated petroleum, chemicals and coal mining operations. Exploration and production operations consist of exploring, developing and producing crude oil and natural gas and marketing natural gas. Refining, marketing and transportation operations relate to refining crude oil into finished petroleum products, marketing crude oil, natural gas and transporting crude oil, natural gas and petroleum products. Chemical operations include manufacture and marketing of commodity petrochemicals, plastics for industrial uses and fuel and lubricant oil additives. The Other operations consist of coal mining operations, power generation business, worldwide cash management and debt financing activities, corporate administrative functions, insurance operations, real estate activities and technology companies.

Chevron Corp.

Chevron is drawing attention as traders react to oil-price swings tied to Middle East conflict and supply risks around the Strait of Hormuz, with some viewing potential disruptions as supportive for energy stocks and others wary that easing tensions or falling crude could pressure shares. Chevrons planned expansion in Venezuela is another recurring topic, though traders debate its long-term potential and execution risks.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

Rising Treasury yields and mortgage-backed-securities repricing are weighing on AGNC, with traders pointing to falling book value and leverage as risks behind the sharp selloff. Some fear the monthly dividend could be cut, while others view the decline as an oversold buying opportunity and continue accumulating for the yield.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

NVAX rose in sympathy with a broader vaccine-stock rally after a report on an NIH push to accelerate personalized cancer vaccines; traders also speculated that Novavaxs Matrix-M platform could benefit, though the company has no cancer-vaccine program. Short-squeeze claims and hopes around Sanofis COVID-flu trial also circulated, but some traders viewed the move as sector-driven and cautioned that gains could fade.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is drawing attention amid a volatile rebound and hopes for a broader altcoin rally, with traders watching for a breakout and pointing to Suis AI-agent and payments adoption narratives, including reported Samsung, Google Cloud, and Tether integrations. Bullish dip-buying and squeeze talk compete with concerns about token unlocks, tokenomics, weak relative performance, and network reliability.

Zoracles

A sharp, high-volume move in ZORA has sparked breakout and short-squeeze speculation, while skeptics warn that the volatile rallies may be short-lived. Some traders point to Zoras expansion into Solana-based attention markets, though they question whether that product creates value for ZORA token holders.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires shares are drawing attention for their weak, volatile trading despite contract and partnership headlines, including follow-on solar-array work for Axiom Space. Traders debate whether ATM share sales and broader small-cap weakness are weighing on the stock, while bulls point to its growing contract pipeline and view the pullback as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer

ABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1%

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totaling 914,989 shares, an increase of 40.1% from the March 31st total of 653,203 shares. Currently, 12.6% of the company's...

HC Wainwright Reiterates "Buy" Rating for Actuate Therapeutics (NASDAQ:ACTU)

HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Actuate Therapeutics in a research note on Wednesday...

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.read...

Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Actuate Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU

Voss Capital LP raised its holdings in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 213.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities...

Actuate Therapeutics (NASDAQ:ACTU) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Actuate Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Actuate Therapeutics (NASDAQ:ACTU) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded Actuate Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y

MTD beats Q4 estimates as adjusted EPS jumps 8% Y/Y and sales rise to $1.13B, led by solid growth across Laboratory, Industrial and Food Retail.

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Actuate Therapeutics Inc.

Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$ACTU Big hit here afterhours on a huge offering - basically triples the amount of shares. 
 
In theory sounds bad but a lot of these huge offering situation end up playing as it portends overall good news. Note this comes on the heels of an announcement this morning that they'll be presenting trial data at a conference in a few weeks...

Brian Badtrader

$ACTU , need cash badly before September 30th. Management  selling ATM Whatever price they get to keep thier lousy and high paid job. Reverse split or cheater 11 in cards for sure.

saul goodman

$ACTU My mistake about data presentation upcoming, I was looking at the wrong ticker's news.  
  
They offering part is accurate... and definitely still interesting that they went so big with it. Seems like that should normally inflict a bigger hit than just 23% down... delayed reaction or is there something cooking behind the scenes???

$ACTU  
 
Wow.  From +17% to -1.5% in a flash.  The fuckery is really something to behold here.  Added.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACTU Actuate Therapeutics Inc.

Fundamentals

Latest ACTU News